Drug Profile
Dexlansoprazole injection - Jiangsu Aosaikang Pharmaceutical
Latest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Jiangsu Aosaikang Pharmaceutical
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Antiulcers; Gastric antisecretories; Pyridines; Small molecules; Sulfoxides
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Erosive oesophagitis; Gastro-oesophageal reflux
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for phase-I development in Erosive-oesophagitis(In volunteers) in China (IV, Injection)
- 28 Feb 2020 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux(In volunteers) in China (IV, Injection)
- 30 Aug 2019 Chemical structure information added